Results 21 to 30 of about 1,610,894 (277)
Background Transforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses.
Stefania Canè +3 more
doaj +1 more source
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer [PDF]
Tumor-associated or -infiltrating lymphocytes (TALs or TILs) co-express multiple immune inhibitory receptors that contribute to immune suppression in the ovarian tumor microenvironment (TME). Dual blockade of PD-1 along with LAG-3 or CTLA-4 has been shown to synergistically enhance T-cell effector function, resulting in a delay in murine ovarian tumor ...
Huang, Ruea-Yea +4 more
openaire +2 more sources
Combinations using checkpoint blockade to overcome resistance [PDF]
The advent of immunotherapy for cancer represented a paradigm shift in the treatment approach of neoplasia. Immune-checkpoint inhibitors (ICIs) were demonstrated to significantly improve outcomes, including overall survival across several cancer types ...
Morganti S., Curigliano G.
core +1 more source
Immune checkpoint inhibitors become a standard therapy for malignant melanoma. As immune checkpoint inhibitor monotherapies proved to have limited efficacy in significant portion of patients, it is envisaged that combination with other therapeutic ...
Hye Suk Hwang +10 more
doaj +1 more source
It has been intensively reported that the immunosuppressive tumor microenvironment (TME) results in tumor resistance to immunotherapy, especially immune checkpoint blockade and chimeric T cell antigen therapy.
Yalei Zhang +4 more
doaj +1 more source
Abstract 2341: Elevated immune activity following an anticancer combination therapy of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21), and immune checkpoint blockade [PDF]
Abstract Background: Coxsackievirus A21 (CAVATAKTM) is a bio-selected oncolytic immunotherapy virus. Following intravenous (i.v) infusion, CAVATAK preferential infects ICAM-1 expressing tumor cell, resulting in tumor cell lysis and a systemic immune-mediated anti-tumor response.
Min Yuan Quah +4 more
openaire +1 more source
Checkpoint inhibition in hematologic malignancies
Checkpoint inhibitor therapy has emerged as an effective therapeutic strategy for many types of malignancies, especially in solid tumors. Within the last two decades, numerous monoclonal antibody drugs targeting the CTLA-4 and PD-1/PD-L1 checkpoint ...
Aaron Tsumura +3 more
doaj +1 more source
Nucleic acid-based immune checkpoint blockade: Progress and potential
Engaging the immune system through checkpoint blockade has become a standard of care in the treatment of many tumors. Traditionally, immune checkpoint blockade involves the use of monoclonal antibodies and whilst these have been extremely successful ...
Adam A. Walters +5 more
core +1 more source
Background: Epithelial-mesenchymal transition (EMT) is critical for cancer cell metastasis. Recently, EMT was reported to be associated with the inflammatory tumour microenvironment and, therefore, might be a predictive biomarker for immune checkpoint ...
Hong Peng +13 more
doaj +1 more source
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Purpose:G9a histone methyltransferase exerts oncogenic effects in several tumor types and its inhibition promotes anticancer effects. However, the impact on checkpoint inhibitor blockade response and the utility of G9a or its target genes as a biomarker ...
Kamal, Nabilah Ahmad +31 more
core +1 more source

